| 000 | 01879 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515163211.0 | ||
| 264 | 0 | _c20090616 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/cncr.24266 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGarg, Ravin | |
| 245 | 0 | 0 |
_aAdults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. _h[electronic resource] |
| 260 |
_bCancer _cMay 2009 |
||
| 300 |
_a2147-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 1 |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 19 |
| 650 | 0 | 4 |
_aCyclophosphamide _xtherapeutic use |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDexamethasone _xtherapeutic use |
| 650 | 0 | 4 |
_aDoxorubicin _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 | _aTranslocation, Genetic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xtherapeutic use |
| 700 | 1 | _aKantarjian, Hagop | |
| 700 | 1 | _aThomas, Deborah | |
| 700 | 1 | _aFaderl, Stefan | |
| 700 | 1 | _aRavandi, Farhad | |
| 700 | 1 | _aLovshe, Denise | |
| 700 | 1 | _aPierce, Sherry | |
| 700 | 1 | _aO'Brien, Susan | |
| 773 | 0 |
_tCancer _gvol. 115 _gno. 10 _gp. 2147-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.24266 _zAvailable from publisher's website |
| 999 |
_c18736316 _d18736316 |
||